Quantcast

Latest Pegfilgrastim Stories

2010-03-10 12:13:34

Multicenter trial led by St. Jude Children's Research Hospital investigators may change neutropenia treatment for all childhood cancer patients For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy. "Cool," Sabrina told Sheri Spunt, M.D., an associate member of the St. Jude Department of Oncology, after hearing the news and...

2010-02-16 04:11:00

DALLAS, February 16, 2010 /PRNewswire/ -- - ReportsandReports announce to have Pipeline/Commercial Insight: Supportive Care in Oncology - Innovation and market growth limited to bone metastases management and emerging supportive care challenges ( http://www.reportsandreports.com/market-reports/pipeline-commercial-insight-s upportive-care-in-oncology-innova/) Market Research Report in its store (Due to the length of this URL, it may be necessary to copy and paste this hyperlink...

2009-09-30 07:47:00

LAKE FOREST, Ill., Sept. 30 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced the acquisition of worldwide rights to a biogeneric version of filgrastim and an affiliated European manufacturing facility from PLIVA Hrvatska d.o.o. (Zagreb, Croatia) (ZSE: PLVA-R-A), a move that will help extend Hospira's reach and vertical integration in biogenerics. Financial terms of the agreement were not...

2009-09-21 06:00:00

SAN CARLOS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that it will be hosting a conference call to discuss today's announcement of a new partnership for NKTR-118 and NKTR-119. The call will begin at 8:30 a.m. Eastern Time (ET)/5:30 a.m. Pacific Time (PT). The live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page of Nektar's website: http://www.nektar.com. The web broadcast of the...

2008-07-11 18:00:35

Amgen (NASDAQ:AMGN) today announced that it has reached an agreement to settle its outstanding antitrust litigation with Ortho Biotech Products L.P. (Ortho Biotech). Ortho Biotech, a subsidiary of Johnson & Johnson (NYSE: JNJ), had alleged that discounts offered to oncology clinics on Amgen's Neupogen and Neulasta and Aranesp products violated antitrust laws. Under terms of the agreement, Amgen will pay Ortho Biotech $200 million and the pending litigation in New Jersey District...

2005-10-13 13:28:10

By Bill Berkrot NEW YORK (Reuters) - Johnson & Johnson has sued Amgen, accusing the world's largest biotechnology company of hampering sales of J&J's anemia drug, Procrit, by using anti-competitive practices in the way it sells its own anemia drugs to physicians. Both Procrit and Amgen's Aranesp are used to boost production of red blood cells in patients suffering anemia as a side effect of chemotherapy. In a lawsuit filed on Tuesday in Federal District Court in New Jersey,...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related